In an interview with PharmaShots, Garret Hampton, President of Clinical Next-Generation Sequencing and Oncology at Thermo Fisher Scientific share his views on multiyear agreement with AstraZeneca to co-develop NGS-based CDx […]readmore
Tags : Thermo Fisher Scientific
Shots: The companies signed an agreement to ensure non-exclusive commercial access to Thermo Fisher’s Gibco CTS Dynabeads CD3/CD28 The focus of the agreement is to support clinical development & commercial […]readmore
Shots: Thermo Fisher acquires Mesa Biotech for $450M in cash. Mesa Biotech will receive an additional ~$100M in cash on the completion of milestones while the transaction is expected to […]readmore
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it The outbreak of the respiratory disease was first detected […]readmore
Shots: Under the amended agreement, the offer price increased from $44.5 to $49/QIAGEN share in cash, representing a premium of 35% to the closing price of QIAGEN’s ordinary shares on […]readmore
Shots: The alliance will validate multiple biomarkers to be used in Thermo Fisher’s Oncomine Dx Target Test, which will be used to identify variant-positive patients for enrollment into clinical studies […]readmore
Shots: Thermo Fisher to acquire QIAGEN in an all-cash transaction for $43.3/ share, making a total deal value ~$11.5B with a premium of 23% to the closing price of QIAGEN’s […]readmore